bnt323
mAbexperimentalADC
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
2
Phase 4
0
Earliest trial started Jan 29, 2024 (NCT06265428)
Timeline
Indications
Mechanism of action
ERBB2 inhibitor
Chemistry & pharmacology
- Payload
- unclear
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06827236 | Phase 1/Phase 2 (Phase 2) | Apr 30, 2025 | Biontech, Biotheus, DualityBio Inc. |
| NCT06340568 | Phase 3 | Nov 30, 2024 | Biontech, DualityBio Inc. |
| NCT06265428 | Phase 3 | Jan 29, 2024 | Biontech, DualityBio Inc. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Biontech | For profit | 3 | 2 | 2 | 2024 |
| DualityBio Inc. | For profit | 3 | 1 | 2 | 2024 |
| Biotheus | For profit | 1 | 0 | 1 | 2025 |
3 organizations
Page 1 / 1